Clinical Validation of Digital PCR-Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results.

Clin Cancer Res · 2026 · PMC13040216 · PMID 41662447

Europe PMC DOI

hedged sentences

0.1300

closest p · 2.6× alpha

0.2000

boldest claim

The sentences

showed a trendP = 0.130not close (p > 0.1)

Patients with no detectable ctDNA at any time point postoperatively showed a trend toward improved RFS (RFS = 85%) compared with those with detectable ctDNA (58%), with an HR of 0.34 (95% CI, 0.13–0.92; P = 0.130).

also in 53,322 other papers

did not reach statistical significanceP = 0.20not close (p > 0.1)

The OS at 5 years was 100% and 52% in patients who cleared and did not clear, respectively, but it did not reach statistical significance ( P = 0.20; HR, 0.26; 95% CI, 0.046–1.53; Fig. 5B ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.